title: Naloxone interaction with pituitary response to TRH and LHRH test in patients with polycystic ovary syndrome.
abstract: The response of TSH, PRL, LH and FSH to combined test with LHRH (Relefact LH-RH, HOECHST; 0.1 mg) and TRH (Relefact TRH, HOECHST; 0.2 mg) was examined before (day I) and after naloxone (Narcanti, DUPONT) bolus of 0.8 mg (day III) in 8 patients with polycystic ovary syndrome (POC) diagnosed by established criteria (hirsutism, oligoamenorrhoea, ultrasound appearance of polycystic ovary and serum LH/FSH greater than 2.0). TSH (RIA-INEP), PRL (MAIA-SERONO), LH (MAIA-SERONO) and FSH (MAIA-SERONO) were determined at -15, 0, 10, 20, 30, 45, 60, 90 and 120 min. The hormone responses were calculated as the areas under hormone curves and tested with Wilcoxon sum rank test. No significant difference was found in the hormone responses before and after naloxone injection. In terms of absolute values lower TSH level was found at 30 min after naloxone administration (14.7 +/- 12.0 vs. 9.73 +/- 7.61; P less than 0.05). In conclusion, our data based on short term naloxone application argue against the significant alteration of the opioid activity in patients with POC.
authors.affiliation: Institute of Endocrinology, Diabetes and Diseases of Metabolism, University Clinical Center, Belgrade, Yugoslavia.
authors.forename: D
authors.initials: D
authors.lastname: Micić
authors.forename: V
authors.initials: V
authors.lastname: Popović
authors.forename: S
authors.initials: S
authors.lastname: Minić
authors.forename: M
authors.initials: M
authors.lastname: Sumarac
authors.forename: A
authors.initials: A
authors.lastname: Kendereski
authors.forename: S
authors.initials: S
authors.lastname: Damjanović
authors.forename: D
authors.initials: D
authors.lastname: Manojlović
authors.forename: J
authors.initials: J
authors.lastname: Mićić
mesh_terms: D000328:Adult; D005260:Female; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D007987:Gonadotropin-Releasing Hormone; D006801:Humans; D007986:Luteinizing Hormone / Q000378:metabolism; D009270:Naloxone / Q000494:pharmacology*; D010902:Pituitary Gland / Q000187:drug effects / Q000378:metabolism*; D011085:Polycystic Ovary Syndrome / Q000378:metabolism*; D011388:Prolactin / Q000378:metabolism; D013972:Thyrotropin / Q000378:metabolism; D013973:Thyrotropin-Releasing Hormone
chemical_list: D007987:Gonadotropin-Releasing Hormone; D009270:Naloxone; D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013972:Thyrotropin